SCHEMBL683924

SCHEMBL683924

CC(Cc1cccc(Cl)c1)NCCn1cnc2c1c(=O)n(C)c(=O)n2C

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.67
▸ L3MBTL1 Q9Y468 2/20 0.67
▸ HTT P42858 2/20 0.67
▸ UBE2N P61088 2/20 0.67
▸ GLA P06280 1/20 0.67
▸ RXFP1 Q9HBX9 3/20 0.55
▸ ALDH1A1 P00352 2/20 0.55
▸ ADORA2B P29275 4/20 0.54
▸ MAPK1 P28482 3/20 0.53
▸ LMNA P02545 2/20 0.53
▸ MAOA P21397 2/20 0.52
▸ MAOB P27338 2/20 0.52
▸ TSHR P16473 1/20 0.51
▸ TP53 P04637 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL682774 0.88 LMNA (0.66) SMN1; SMN2L3MBTL1HTTUBE2NGLA
Fenethylline SCHEMBL149145 0.88 ALDH1A1 (0.65) SMN1; SMN2L3MBTL1HTTUBE2NGLA
Fenethylline SCHEMBL121386 0.87 ALDH1A1 (0.64) SMN1; SMN2L3MBTL1HTTUBE2NGLA
Fenethylline SCHEMBL155920 0.87 ALDH1A1 (0.64) SMN1; SMN2L3MBTL1HTTUBE2NGLA
SCHEMBL683921 0.87 RXFP1 (0.68) SMN1; SMN2L3MBTL1HTTUBE2NGLA
Fenethylline SCHEMBL28154439 0.85 SMN1; SMN2 (0.55) SMN1; SMN2L3MBTL1HTTUBE2NGLA
SCHEMBL684304 0.84 RXFP1 (0.55) SMN1; SMN2L3MBTL1HTTUBE2NGLA
Fenethylline SCHEMBL14057908 0.84 ALDH1A1 (0.60) SMN1; SMN2L3MBTL1HTTUBE2NGLA
Fenethylline SCHEMBL1934850 0.84 ALDH1A1 (0.60) SMN1; SMN2L3MBTL1HTTUBE2NGLA
SCHEMBL682776 0.83 ADORA2B (0.50) SMN1; SMN2HTTUBE2NRXFP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN BRAINCELLS INC. (US) 2011-11-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269717-A1 NEUROGENESIS BY MODULATING ANGIOTENSIN NGF, DCX, BDNF SMN1; SMN2 907/4885L3MBTL1 4624/4885HTT 751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback